



QIAGEN Marseille to focus on innovative biomarkers development and Next Generation Sequencing IVD applications

MARSEILLE, France, January 10, 2013 — QIAGEN Marseille (Paris: ALIPS) today announced its intent to focus on innovative biomarkers development and Next Generation Sequencing IVD applications.

This decision will allow QIAGEN Marseille to further focus its resources and accelerate the development and commercialization of its strategic oncology and personalized healthcare programs, in particular Next Generation Sequencing (NGS) for cancer diagnostics, a market segments having a significant growth and business potential.

Earlier this month QIAGEN Marseille also announced a partnership and licensing option with Mayo Clinic in Rochester, Minnesota, for the use of the IDH1 and IDH2 biomarkers to diagnose and guide the treatment of cholangiocarcinoma. This collaboration with one of the world most renowned research and clinical institute is a testimony of QIAGEN Marseille's continuous commitment to the development of high medical value and innovative molecular diagnostic tests.

In light of this strategic focus and following an in-depth review of the development project for the Genomic Grade, a molecular test intended to provide prognostic information in Breast cancer, QIAGEN Marseille determined that despite its scientific value it was not aligned with the corporate technical and business objectives of the company. QIAGEN Marseille will work with its scientific and academic partners to establish the best way to continue fulfilling its contractual and scientific obligations, in particular the future delivery of the test in ongoing clinical trials.

Vincent Fert CEO of QIAGEN Marseille and VP Personalized Healthcare Program Lead of QIAGEN NV stated: *"With this decision, our Marseille R&D team can now fully focus on further building our franchise in our core market segments. We are also in a position to reinforce our research activities in the NGS field, focusing on bringing these breakthrough technologies to the IVD standards, a promise which holds significant growth and value potential for our company."*

About QIAGEN Marseille

QIAGEN Marseille develops molecular diagnostic tests designed to map diseases in order to guide patients and oncologists' decisions along their complex therapeutic path. With more than 60 tests already used routinely worldwide for the diagnosis, prognosis and follow-up of thousands of patients with blood cancer, QIAGEN Marseille is also developing diagnostic tools targeting other cancers. Its goal is to provide information, remaining unavailable until now, to sustain the development of personalized medicine.

Further information can be found at www.qiagenmarseille.com

Contacts :**QIAGEN Marseille**

Vincent Fert
CEO
Tel : + 33 (0)4 91 29 30 90
vincent.fert@qiagen.com

Press relations
Marielle Bricman, ATCG Press
Mob. : + 33 (0)6 26 94 18 53
mb@atcg-partners.com

